Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00524017 · OUTCOME

Survival

Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract · Source last updated 2020-03-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to year 5 years post-treatment

Analysis population: No patients were followed for this outcome measure

Groups in this outcome

Arm I (Treatment)

Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. cetuximab: given IV

Arm II (Control)

Patients receive regular follow-up care

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Treatment)0
Arm II (Control)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
groups
  1. description
    Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. cetuximab: given IV
    id
    OG000
    title
    Arm I (Treatment)
  2. description
    Patients receive regular follow-up care
    id
    OG001
    title
    Arm II (Control)
population Description
No patients were followed for this outcome measure
reporting Status
POSTED
time Frame
Up to year 5 years post-treatment
title
Survival
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice